Enlivex shares rise 14.42% intraday after approving name change to Enlivex Ltd. and securing regulatory approvals.

Enlivex surged 14.42% intraday, following shareholder approval on February 3, 2026, to rename to Enlivex Ltd., receipt of a certificate from the Israeli Registrar on February 10, and filing of a Form 6-K with the SEC on February 23 to confirm the name change. The biopharmaceutical company, which focuses on therapeutic product development, reported 2024 financials showing a $15.3 million EBITDA loss and $13.1 million negative free cash flow, reflecting R&D investments.